The FDA sent 30 warning letters to GLP-1 compounders on February 20, 2026, flagging violations including claims of "same active ingredients" as brand-name drugs, language implying therapeutic equivalence, and statements implying FDA approval of compounded products
Ribeiro ASF, Zerolo BE, Lpez-Espuela F, Snchez R, Fernandes VS
Why This Matters GLP-1 medications work only as long as patients take them
While biologically interesting, the challenge is that theres often no reliable way to verify these FDA-banned medications
According to filed complaints reviewed in federal court records, some patients describe lives that changed dramatically after starting these medications
Knob-billed Duck ( Sarkidiornis melanotos ), version 1.0